Mastiha has efficacy in immune-mediated inflammatory diseases through a microRNA-155 Th17 dependent action.

Autor: Amerikanou C; Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece., Papada E; Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece., Gioxari A; Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece., Smyrnioudis I; Chios Mastic Gum Growers Association, Chios, Greece., Kleftaki SA; Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece., Valsamidou E; Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece., Bruns V; Sanofi Research and Development, Industriepark Hoechst, D-65926 Frankfurt, Germany., Banerjee R; Perspectum Ltd, Oxford, UK., Trivella MG; ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; Institute of Clinical Physiology National Research Council, Pisa, Italy., Milic N; Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia., Medić-Stojanoska M; Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia; Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Centre of Vojvodina, Novi Sad, Serbia., Gastaldelli A; Institute of Clinical Physiology National Research Council, Pisa, Italy., Kannt A; Sanofi Research and Development, Industriepark Hoechst, D-65926 Frankfurt, Germany; Fraunhofer Institute of Translational Medicine and Pharmacology ITMP, Frankfurt, Germany., Dedoussis GV; Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece. Electronic address: dedousi@hua.gr., Kaliora AC; Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece. Electronic address: akaliora@hua.gr.
Jazyk: angličtina
Zdroj: Pharmacological research [Pharmacol Res] 2021 Sep; Vol. 171, pp. 105753. Date of Electronic Publication: 2021 Jul 02.
DOI: 10.1016/j.phrs.2021.105753
Abstrakt: Mastiha is a natural nutritional supplement with known anti-inflammatory properties. Non-alcoholic fatty liver disease (NAFLD) and Inflammatory bowel disease (IBD) are immune mediated inflammatory diseases that share common pathophysiological features. Mastiha has shown beneficial effects in both diseases. MicroRNAs have emerged as key regulators of inflammation and their modulation by phytochemicals have been extensively studied over the last years. Therefore, the aim of this study was to investigate whether a common route exists in the anti-inflammatory activity of Mastiha, specifically through the regulation of miRNA levels. Plasma miR-16, miR-21 and miR-155 were measured by Real-Time PCR before and after two double blinded and placebo-controlled randomized clinical trials with Mastiha. In IBD and particularly in ulcerative colitis patients in relapse, miR-155 increased in the placebo group (p = 0.054) whereas this increase was prevented by Mastiha. The mean changes were different in the two groups even after adjusting for age, sex and BMI (p = 0.024 for IBD and p = 0.042). Although the results were not so prominent in NAFLD, miR-155 displayed a downward trend in the placebo group (p = 0.054) whereas the levels did not changed significantly in the Mastiha group in patients with less advanced fibrosis. Our results propose a regulatory role for Mastiha in circulating levels of miR-155, a critical player in T helper-17 (Th17) differentiation and function.
(Copyright © 2021 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: